(607b) Formulation, Characterization and Evaluation of Curcumin-Loaded &gamma-Cyclodextrin Liposomal Nanoparticles On Osteosarcoma Cell Lines

Curcumin, the constituent of Curcuma longa, has been shown to possess potent anti-neoplastic activity against a number of tumors including prostate, breast and colon cancer. Widespread clinical application of curcumin has been limited due to poor aqueous solubility and low systemic bioavailability. Reports so far indicated extremely low serum levels (22 - 41 ng/ml) of curcumin, even after high amounts (8 g) of oral administration due to its low water solubility (11 ng/ml). Conjugates of curcumin with macromolecules, nano-formulations, cyclodextrins, liposomes and hydrogels are being employed to make the highly hydrophobic drug more water-soluble, thereby increasing its circulation time and bio-availability. In spite of curcumin's effect on broad range of tumors, the anticancer potential of curcumin against osteosarcoma (OS) is not fully explored. Osteosarcoma occurs as a second malignant neoplasm due to a genetic pre-disposition and/or as a consequence of prior cancer therapy. In the current study, we prepared and estimated the potential of liposomal curcumin against osteosarcoma cell lines. We have explored the concept of drug-in-cyclodextrin-in-liposome (DCL) preparations, imaging the complex through cryo transmission electron microscopy. We have also developed a novel tubular liposome delivery technique for curcumin. The presentation will focus mainly on formulation, characterization by cryo-transmission electron microscopy, and the effect of various curcumin formulations on cancer of mesenchymal / epithelial origin and toxicity study on normal human cells that are treated as control. Analysis of cell death pathways used by the OS cell line in response to different curcumin formulations will be described.